KDM5A : A Master Epigenetic Regulator of Th2 Immunity and Allergic Disease Pathogenesis
Immunology · 2026
DOI: 10.1111/imm.70061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2026. Verfasst von Jiangqi Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Longgang ENT Hospital & Shenzhen ENT Institute, Shenzhen, China. Hauptthemen laut MEDLINE: Th2 Cells, Epigenesis, Genetic, Retinoblastoma-Binding Protein 2, Hypersensitivity. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Interleukin‐4 (IL‐4) drives Th2 polarisation and allergic inflammation, yet the epigenetic mechanisms regulating Il4 transcription in CD4 + T cells remain unclear. While STAT6 and GATA3 are canonical transcriptional regulators, lysine‐specific demethylase 5A (KDM5A), an H3K4‐specific demethylase, has not been linked to Th2 immunity. Here, we investigate KDM5A's role in IL‐4 production and allergic airway disease (AA). Using DO11.10 TCR‐transgenic mice and CD4 + T cell‐specific Kdm5a‐knockout models, we assessed KDM5A's role in IL‐4 transcription. Chromatin immunoprecipitation (ChIP)‐qPCR evaluated H3K4 demethylation at the Il4 promoter. Cross‐ELISA quantified IL‐4 secretion, and ubiquitination assays analysed KDM5A stability. Lactobacilli‐derived DNA (LgDNA) was administered to disrupt the USP7‐KDM5A axis in AA models. The results showed that KDM5A deficiency abolished TCR activation‐induced IL‐4 production, impairing Th2 polarisation. Mechanistically, KDM5A maintained H3K4 hypomethylation at the Il4 promoter, facilitating STAT6/GATA3 recruitment. TCR signalling enhanced KDM5A promoter occupancy via USP7‐mediated deubiquitination. USP7 stabilisation of KDM5A elevated H3K4 demethylation and IL‐4 transcription, driving AA pathogenesis. LgDNA suppressed USP7 activity, reducing KDM5A promoter binding by 65% and airway inflammation by 72%. In summary, KDM5A acts as an epigenetic rheostat of Th2 immunity, where USP7‐dependent stabilisation licenses STAT6/GATA3 access to the Il4 promoter during TCR activation. Targeting the USP7‐KDM5A axis with LgDNA selectively suppresses pathogenic Th2 responses while preserving physiological IL‐4 functions. Our findings define a novel epigenetic mechanism for allergic disease and establish microbiome‐derived LgDNA as a precision therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy, Longgang ENT Hospital & Shenzhen ENT Institute, Shenzhen, China.
- Department of General Practice Medicine, Third Affiliated Hospital of Shenzhen University (Luohu Hospital), Shenzhen, China.
- State Key Laboratory of Respiratory Diseases Allergy Division at Shenzhen University and Institute of Allergy & Immunology, Shenzhen University School of Medicine, Shenzhen Key Laboratory of Allergy & Immunology, Shenzh…
ORCID-Profile: Pingchang Yang
Zitieren
APA
Liu, J., Liu, Z., Geng, X., Wu, Y., Mo, L., Liao, Y., Liu, Y., & Yang, P. (2026). KDM5A : A Master Epigenetic Regulator of Th2 Immunity and Allergic Disease Pathogenesis. Immunology. https://doi.org/10.1111/imm.70061
Vancouver
Liu J, Liu Z, Geng X, Wu Y, Mo L, Liao Y, et al. KDM5A : A Master Epigenetic Regulator of Th2 Immunity and Allergic Disease Pathogenesis. Immunology. 2026. doi:10.1111/imm.70061
BibTeX
@article{Liu2026,
author = {Liu, Jiangqi and Liu, Zhiqiang and Geng, Xiaorui and Wu, Yongjin and Mo, Lihua and Liao, Yun and Liu, Yu and Yang, Pingchang},
title = {KDM5A : A Master Epigenetic Regulator of Th2 Immunity and Allergic Disease Pathogenesis},
journal = {Immunology},
year = {2026},
doi = {10.1111/imm.70061}
}
EUVIMED